Daniel Yokell

Company: Telix Pharmaceuticals

Job title: VP, Theranostic Neurooncology

Seminars:

Panel Discussion: Addressing the Peaks & Troughs of the GBM Space: What is Promising & Where is Innovation Necessary? 9:00 am

Highlighting emerging therapies such as immunotherapy and personalized medicine showing potential in GBM treatment Discussing barriers such as the blood-brain barrier, tumor resistance, and high recurrence rates Exploring key areas for innovation, including diagnostics, drug delivery, and combination therapiesRead more

day: Conference Day 1

Novel Approaches to Seeing & Treating Gliomas for Improved Characterization 1:45 pm

Highlighting Pixclara® (18F-floretyrosine, 18F-FET) as first-in-class in the US amino acid PET radiotracer for the characterization of progressive or recurrent glioma from treatment related changes in adult and pediatric patients (US NDA under review; approval expected Q2 2025) Developing radiopharmaceutical theranostics for Neurooncology targeting LAT-1 receptor in GBM with Betas: TLX-101 (131I iodofalan) Developing radiopharmaceutical…Read more

day: Conference Day 1